Table 1 Demographic, clinical and pathological characteristics of 201 patients undergoing neoadjuvant therapy for GC by Helicobacter pylori infection status
Variables | Total (n = 201) | Negative (n = 132) | Positive (n = 69) | P |
|---|---|---|---|---|
Sex | 0.580 | |||
Female | 45 | 28 (21.21) | 17 (24.64) | |
Male | 156 | 104 (78.79) | 52 (75.36) | |
Age | 0.078 | |||
< 60 | 90 | 65 (49.24) | 25 (36.23) | |
≥ 60 | 111 | 67 (50.76) | 44 (63.77) | |
Blood group | 0.467 | |||
A | 65 | 45 (34.09) | 20 (28.99) | |
AB | 22 | 12 (9.09) | 10 (14.49) | |
B | 57 | 40 (30.30) | 17 (24.64) | |
O | 57 | 35 (26.52) | 22 (31.88) | |
Hypertension | 0.480 | |||
No | 146 | 98 (74.24) | 48 (69.57) | |
Yes | 55 | 34 (25.76) | 21 (30.43) | |
Diabetes | 0.580 | |||
No | 174 | 113 (85.61) | 61 (88.41) | |
Yes | 27 | 19 (14.39) | 8 (11.59) | |
Drinking | 0.208 | |||
No | 113 | 70 (53.03) | 43 (62.32) | |
Yes | 88 | 62 (46.97) | 26 (37.68) | |
Smoking | 0.379 | |||
No | 105 | 66 (50.00) | 39 (56.52) | |
Yes | 96 | 66 (50.00) | 30 (43.48) | |
Family history | 0.173 | |||
No | 158 | 100 (75.76) | 58 (84.06) | |
Yes | 43 | 32 (24.24) | 11 (15.94) | |
BMI | 0.360 | |||
Abnormal | 93 | 58 (43.94) | 35 (50.72) | |
Normal | 108 | 74 (56.06) | 34 (49.28) | |
Surgical procedure | 0.884 | |||
Distal | 98 | 66 (50.00) | 32 (46.38) | |
Proximal | 20 | 13 (9.85) | 7 (10.14) | |
Total | 83 | 53 (40.15) | 30 (43.48) | |
Tumor maximum diameter | 0.819 | |||
> 4 | 75 | 50 (37.88) | 25 (36.23) | |
≤ 4 | 126 | 82 (62.12) | 44 (63.77) | |
Neoadjuvant therapy cycle | 0.277 | |||
> 4 | 31 | 23 (17.42) | 8 (11.59) | |
≤ 4 | 170 | 109 (82.58) | 61 (88.41) | |
Type differentiation | 0.483 | |||
High | 5 | 3 (2.27) | 2 (2.90) | |
Moderate | 43 | 30 (22.73) | 13 (18.84) | |
Poor | 135 | 90 (68.18) | 45 (65.22) | |
Unknown | 18 | 9 (6.82) | 9 (13.04) | |
Lauren | 0.771 | |||
Diffused | 40 | 27 (20.45) | 13 (18.84) | |
Intestinal | 63 | 44 (33.33) | 19 (27.54) | |
Mixed | 36 | 23 (17.42) | 13 (18.84) | |
Unknown | 62 | 38 (28.79) | 24 (34.78) | |
Lymph node transfer | ||||
No | 105 | 65 (49.24) | 40 (57.97) | |
Yes | 96 | 67 (50.76) | 29 (42.03) | |
Her2 expression | 0.344 | |||
Negative | 134 | 85 (64.39) | 49 (71.01) | |
Positive | 67 | 47 (35.61) | 20 (28.99) | |
Prior eradication therapy | 0.789 | |||
Yes | 90 | 60 (15.91) | 30 (14.49) | |
No | 111 | 72 (84.09) | 39 (85.51) | |
Neoadjuvant therapy regimen | 0.296 | |||
Chemo-Immunotherapy | 86 | 53 (40.15) | 33 (47.83) | |
Chemotherapy | 115 | 79 (59.85) | 36 (52.17) | |
Pathological tumor stage (ypT) | 0.222 | |||
0–1 | 59 | 35 (26.52) | 24 (34.78) | |
2–4 | 142 | 97 (73.48) | 45 (65.22) | |
Pathological node stage (ypN) | 0.165 | |||
0 | 100 | 61 (46.21) | 39 (56.52) | |
1–3 | 101 | 71 (53.79) | 30 (43.48) | |
ypTNM | 0.463 | |||
I | 73 | 44 (33.33) | 29 (42.03) | |
II | 46 | 31 (23.48) | 15 (21.74) | |
III | 82 | 57 (43.18) | 25 (36.23) | |
Adverse reaction | 0.818 | |||
No | 139 | 92 (69.70) | 47 (68.12) | |
Yes | 62 | 40 (30.30) | 22 (31.88) | |
TRG | 0.834 | |||
MjHR | 68 | 43 (32.58) | 25 (36.23) | |
NHR | 64 | 42 (31.82) | 22 (31.88) | |
PHR | 69 | 47 (35.61) | 22 (31.88) | |
ORR | 0.030 | |||
CR/PR | 107 | 63 (47.73) | 44 (63.77) | |
SD/PD | 94 | 69 (52.27) | 25 (36.23) | |
pCR | 0.788 | |||
pCR | 33 | 21 (15.91) | 12 (17.39) | |
non-pCR | 168 | 111 (84.09) | 57 (82.61) | |
MPR | 0.914 | |||
MPR | 66 | 43 (32.58) | 23 (33.33) | |
non-MPR | 135 | 89 (67.42) | 46 (66.67) |